An Efficacy and Safety Study of AZD4831 (MPO inhibitor) vs placebo in the treatment of moderate to severe COPD. - CRESCENDO

Study identifier:D6582C00001

ClinicalTrials.gov identifier:NCT05492877

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase 2a Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD4831

Sex

All

Actual enrollment

288

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 14 Nov 2022
Estimated Primary Completion Date: 13 May 2024
Estimated Study Completion Date: 13 May 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria